Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | MPO | P05164 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.65 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.65 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | ACE | P12821 | 4/20 | 0.61 |
| ▸ | ITGB2 | P05107 | 4/20 | 0.60 |
| ▸ | ICAM1 | P05362 | 4/20 | 0.60 |
| ▸ | ITGAL | P20701 | 4/20 | 0.60 |
| ▸ | PPARG | P37231 | 1/20 | 0.59 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Golotimod SCHEMBL14790029 | 1.00 | KDM4E (0.65) | KDM4EMEN1LMNAMPOMAPT | |
| Golotimod SCHEMBL12966340 | 1.00 | KDM4E (0.65) | KDM4EMEN1LMNAMPOMAPT | |
| Golotimod SCHEMBL1768729 | 1.00 | KDM4E (0.65) | KDM4EMEN1LMNAMPOMAPT | |
| Orilotimod SCHEMBL733964 | 1.00 | KDM4E (0.65) | KDM4EMEN1LMNAMPOMAPT | |
| Golotimod SCHEMBL726291 | 1.00 | KDM4E (0.65) | KDM4EMEN1LMNAMPOMAPT | |
| Golotimod SCHEMBL12818886 | 1.00 | KDM4E (0.65) | KDM4EMEN1LMNAMPOMAPT | |
| Golotimod SCHEMBL29622906 | 1.00 | KDM4E (0.65) | KDM4EMEN1LMNAMPOMAPT | |
| Golotimod SCHEMBL726938 | 1.00 | KDM4E (0.65) | KDM4EMEN1LMNAMPOMAPT | |
| Orilotimod SCHEMBL29379690 | 1.00 | KDM4E (0.65) | KDM4EMEN1LMNAMPOMAPT | |
| SCHEMBL645413 | 0.93 | ERAP2 (0.60) | KDM4EMEN1LMNAMPOMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 397 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12548678-B2 | Methods and systems for machine learning analysis of single nucleotide polymorphisms in lupus | AMPEL BIOSOLUTIONS, LLC (US) | 2026-02-10 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| CN-117070570-A | Method for improving transfection efficiency of liposome transfection reagent | 南通大学 | 2023-11-17 | — | — | CN | claimed |
| US-11583544-B2 | Remote loading of sparingly water-soluble drugs into lipid vesicles | CELATOR PHARMACEUTICALS, INC. (US) | 2023-02-21 | — | — | US | claimed |
| US-10760129-B2 | Th17 differentiation markers for acne and uses thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2020-09-01 | — | — | US | claimed |
| US-20170368081-A1 | METHOD FOR TREATING RECURRING SKIN AND MUCOUS MEMBRANE DISEASES CAUSED BY HSV-1 AND HSV-2 | Tets, Viktor Veniaminovich (RU) | 2017-12-28 | — | — | US | claimed |
| US-20140235475-A1 | TH17 DIFFERENTIATION MARKERS FOR ACNE AND USES THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-08-21 | — | — | US | claimed |
| US-20140221231-A1 | TH-17 DIFFERENTIATION MARKERS FOR ROSACEA AND USES THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-08-07 | — | — | US | claimed |
| EP-2723890-A1 | NEW TH17 DIFFERENTIATION MARKERS FOR ACNE AND USES THEREOF | Galderma Research & Development (FR) | 2014-04-30 | — | — | EP | claimed |
| EP-2723889-A1 | NEW TH17 DIFFERENTIATION MARKERS FOR ACNE AND USES THEREOF | Galderma Research & Development (FR) | 2014-04-30 | — | — | EP | claimed |
| EP-2078525-A2 | Treatment of tuberculosis using immunomodulator compounds | SciClone Pharmaceuticals, Inc. (US) | 2009-07-15 | — | — | EP | claimed |
| US-7173013-B2 | Treatment of tuberculosis using immunomodulator compounds | SCICLONE PHARMACEUTICALS, INC. (US) | 2007-02-06 | — | — | US | claimed |
| EP-1420808-A4 | TREATMENT OF TUBERCULOSIS USING IMMUNOMODULATOR COMPOUNDS | SCICLONE PHARMACEUTICALS INC (US) | 2006-06-07 | — | — | EP | claimed |
| US-20040259806-A1 | Treatment of tuberculosis using immunomodulator compounds | SCICLONE PHARMACEUTICALS, INC. | 2004-12-23 | — | — | US | claimed |
| JP-2004537579-A | — | — | 2004-12-16 | — | — | JP | claimed |
| CN-1155571-C | Gamma-glutamyl and beta-aspartyl containing immunomodulator compounds and methods of making the same | ������������ҩ�������ι�˾ | 2004-06-30 | — | — | CN | claimed |
| EP-1420808-A1 | TREATMENT OF TUBERCULOSIS USING IMMUNOMODULATOR COMPOUNDS | Sciclone Pharmaceuticals, Inc. (US) | 2004-05-26 | — | — | EP | claimed |
| WO-2003013572-A1 | TREATMENT OF TUBERCULOSIS USING IMMUNOMODULATOR COMPOUNDS | SCICLONE PHARMACEUTICALS, INC. (US) | 2003-02-20 | — | — | WO | claimed |
| CN-1284943-A | Gamma-glutamyl and beta-aspartyl containing immunomodulator compounds and methods of making the same | WEI EDWARD T (US) | 2001-02-21 | — | — | CN | claimed |
| US-5916878-A | DIPEPTIDE OF EITHER GAMMA-GLUTAMYL-L-TRYPTOPHAN OR BETA-ASPARTYL-L-TRYPTOPHAN; ADMINISTERING TO THE PATIENTS TO REDUCE THE RISKS INFECTIONS FROM MICROORGANISM | Wei, Edward T. (US) | 1999-06-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170368081-A1 | METHOD FOR TREATING RECURRING SKIN AND MUCOUS MEMBRANE DISEASES CAUSED BY HSV-1 AND HSV-2 | PMP22, CUTA, HRH2 | KDM4E 1348/4885MEN1 757/4885LMNA 2929/4885 |
| US-20040259806-A1 | Treatment of tuberculosis using immunomodulator compounds | IFNG, IFNAR1, CD4 | KDM4E 4329/4885MEN1 2589/4885LMNA 4275/4885 |
| US-12548678-B2 | Methods and systems for machine learning analysis of single nucleotide polymorphisms in lupus | SSB, METTL16, TLR9 | KDM4E 2934/4885MEN1 4189/4885LMNA 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.